# SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study

> **NCT00511797** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 249 (actual)

## Conditions studied

- Dysmenorrhea

## Interventions

- **DRUG:** SH T04740B
- **DRUG:** SH T00186DF
- **DRUG:** SH T04740F
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00511797
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2017-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00511797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00511797, "SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00511797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*